Medivolve Inc.
MEDVF
$0.002
$0.000.00%
OTC PK
| 03/31/2024 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 13.82% | 38.18% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 13.82% | 38.18% | |||
| Cost of Revenue | -32.53% | -15.99% | |||
| Gross Profit | 22.22% | 56.48% | |||
| SG&A Expenses | -2.77% | -42.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.23% | -41.35% | |||
| Operating Income | 12.78% | 53.91% | |||
| Income Before Tax | -25.51% | 52.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -25.51% | 52.75% | |||
| Earnings from Discontinued Operations | 95.60% | -206.89% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 33.67% | -60.44% | |||
| Net Income | 88.77% | -135.32% | |||
| EBIT | 12.78% | 53.91% | |||
| EBITDA | 13.82% | 46.28% | |||
| EPS Basic | 88.76% | -135.33% | |||
| Normalized Basic EPS | -18.31% | 63.21% | |||
| EPS Diluted | 88.76% | -128.26% | |||
| Normalized Diluted EPS | -18.31% | 63.21% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||